lawson_ijc_2C_QoL.pdf (394.01 kB)
Download file

Impact of non-cardiovascular disease comorbidity on cardiovascular disease symptom severity: a population-based study.

Download (394.01 kB)
journal contribution
posted on 18.10.2019, 13:09 by C. A. Rushton, U. T. Kadam
OBJECTIVES: Non-cardiovascular comorbidity is common in cardiovascular disease (CVD) populations but its influence on chest pain (CP) and shortness of breath (SOB) symptom-specific physical limitations is unknown. We wanted to test the a priori hypothesis that an unrelated comorbidity would influence symptom-specific physical limitations and to investigate this impact in different severities of CVD. METHOD AND RESULTS: The study was based on 5426 patients from ten family practices, organised into eight a priori exclusive severity groups: (i) no CVD or osteoarthritis (OA) (reference), (ii) index hypertension, ischaemic heart disease (IHD) and heart failure (HF) without OA, (iii) index OA without CVD and (iv) same CVD groups with comorbid OA. The measure of CP physical limitations was Seattle Angina Questionnaire and for SOB physical limitations was the Kansas City Cardiomyopathy Questionnaire. Adjusted baseline associations between the cohorts and symptom-specific physical limitations were assessed using linear regression methods. In the study population, 1443 (27%) reported CP and 2097 (39%) SOB. CP and SOB physical limitations increased with CVD severity in the index and comorbid groups. Compared with the respective index CVD group, the CP physical limitation scores for comorbid CVD groups with OA were lower by: -14.7 (95% CI -21.5, 7.8) for hypertension, -5.5 (-10.4, -0.7) for IHD and -22.1 (-31.0, -6.7) for HF. For SOB physical limitations, comorbid scores were lower by: -9.2 (-13.8, -4.6) for hypertension, -6.4 (-11.1, -1.8) for IHD and -8.8 (-19.3, 1.65) for HF. CONCLUSIONS: CP and SOB are common symptoms, and OA increases the CVD symptom-specific physical limitations additively. Comorbidity interventions need to be developed for CVD specific health outcomes.

Funding

CAR was supported by a National Institute for Health Research (NIHR) Doctoral Fellowship (grant number NIHR-DRF-2012-05-288) (UK) and 2C study and UTK was supported by a National Institute for Health Research (NIHR) Post-Doctoral Fellowship (UK). We thank the practice and patient participants of the 2C study.

History

Citation

Int J Cardiol, 2014, 175 (1), pp. 154-161

Author affiliation

/Organisation/COLLEGE OF LIFE SCIENCES/School of Medicine/Department of Health Sciences

Version

VoR (Version of Record)

Published in

Int J Cardiol

Publisher

Elsevier, International Society for Adult Congenital Heart Disease

eissn

1874-1754

Acceptance date

05/05/2014

Copyright date

2014

Available date

18/10/2019

Publisher version

https://www.sciencedirect.com/science/article/pii/S0167527314009693?via=ihub

Notes

The following are the supplementary data related to this article. Supplementary Table 1. Associations between study groups and symptom physical limitations.

Language

en